Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 181

1.

Molecular and clinical risk factors for recurrence of skull base chordomas: gain on chromosome 2p, expression of brachyury, and lack of irradiation negatively correlate with patient prognosis.

Kitamura Y, Sasaki H, Kimura T, Miwa T, Takahashi S, Kawase T, Yoshida K.

J Neuropathol Exp Neurol. 2013 Sep;72(9):816-23. doi: 10.1097/NEN.0b013e3182a065d0.

PMID:
23965741
2.

Brachyury: A sensitive marker, but not a prognostic factor, for skull base chordomas.

Wang K, Tian K, Wang L, Wu Z, Ren C, Hao S, Feng J, Li J, Wan H, Jia G, Zhang L, Zhang J.

Mol Med Rep. 2015 Sep;12(3):4298-304. doi: 10.3892/mmr.2015.3976. Epub 2015 Jun 22.

3.

T gene isoform expression pattern is significantly different between chordomas and notochords.

Wang K, Hu Q, Wang L, Chen W, Tian K, Cao C, Wu Z, Jia G, Zhang L, Zeng C, Zhang J.

Biochem Biophys Res Commun. 2015 Nov 13;467(2):261-7. doi: 10.1016/j.bbrc.2015.09.178. Epub 2015 Oct 3.

PMID:
26435504
4.

Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study.

Presneau N, Shalaby A, Ye H, Pillay N, Halai D, Idowu B, Tirabosco R, Whitwell D, Jacques TS, Kindblom LG, Brüderlein S, Möller P, Leithner A, Liegl B, Amary FM, Athanasou NN, Hogendoorn PC, Mertens F, Szuhai K, Flanagan AM.

J Pathol. 2011 Feb;223(3):327-35. doi: 10.1002/path.2816. Epub 2010 Nov 24.

PMID:
21171078
5.

Analysis of the fibroblastic growth factor receptor-RAS/RAF/MEK/ERK-ETS2/brachyury signalling pathway in chordomas.

Shalaby AA, Presneau N, Idowu BD, Thompson L, Briggs TR, Tirabosco R, Diss TC, Flanagan AM.

Mod Pathol. 2009 Aug;22(8):996-1005. doi: 10.1038/modpathol.2009.63. Epub 2009 May 1.

6.

Revisiting chordoma with brachyury, a "new age" marker: analysis of a validation study on 51 cases.

Jambhekar NA, Rekhi B, Thorat K, Dikshit R, Agrawal M, Puri A.

Arch Pathol Lab Med. 2010 Aug;134(8):1181-7. doi: 10.1043/2009-0476-OA.1.

PMID:
20670140
7.

Generation of chordoma cell line JHC7 and the identification of Brachyury as a novel molecular target.

Hsu W, Mohyeldin A, Shah SR, ap Rhys CM, Johnson LF, Sedora-Roman NI, Kosztowski TA, Awad OA, McCarthy EF, Loeb DM, Wolinsky JP, Gokaslan ZL, Quiñones-Hinojosa A.

J Neurosurg. 2011 Oct;115(4):760-9. doi: 10.3171/2011.5.JNS11185. Epub 2011 Jun 24.

8.
9.

Expression of ezrin, MMP-9, and COX-2 in 50 chordoma specimens: a clinical and immunohistochemical analysis.

Froehlich EV, Scheipl S, Lazàry A, Varga PP, Schmid C, Stammberger H, Beham A, Bodo K, Schroettner H, Quehenberger F, Windhager R, Liegl B, Leithner A.

Spine (Phila Pa 1976). 2012 Jun 1;37(13):E757-67. doi: 10.1097/BRS.0b013e31824782e1.

PMID:
22228328
10.

Tissue microarray immunohistochemical detection of brachyury is not a prognostic indicator in chordoma.

Zhang L, Guo S, Schwab JH, Nielsen GP, Choy E, Ye S, Zhang Z, Mankin H, Hornicek FJ, Duan Z.

PLoS One. 2013 Sep 23;8(9):e75851. doi: 10.1371/journal.pone.0075851. eCollection 2013.

11.

The brachyury Gly177Asp SNP is not associated with a risk of skull base chordoma in the Chinese population.

Wu Z, Wang K, Wang L, Feng J, Hao S, Tian K, Zhang L, Jia G, Wan H, Zhang J.

Int J Mol Sci. 2013 Oct 25;14(11):21258-65. doi: 10.3390/ijms141121258.

12.

Genetic characterization of skull base chondrosarcomas.

Kanamori H, Kitamura Y, Kimura T, Yoshida K, Sasaki H.

J Neurosurg. 2015 Oct;123(4):1036-41. doi: 10.3171/2014.12.JNS142059. Epub 2015 Jul 10.

PMID:
26162041
13.

Prognostic factors for long-term outcome of patients with surgical resection of skull base chordomas-106 cases review in one institution.

Wu Z, Zhang J, Zhang L, Jia G, Tang J, Wang L, Wang Z.

Neurosurg Rev. 2010 Oct;33(4):451-6. doi: 10.1007/s10143-010-0273-6. Epub 2010 Jul 29.

PMID:
20668904
14.

From notochord formation to hereditary chordoma: the many roles of Brachyury.

Nibu Y, José-Edwards DS, Di Gregorio A.

Biomed Res Int. 2013;2013:826435. doi: 10.1155/2013/826435. Epub 2013 Mar 31. Review.

15.

Diagnosing an extra-axial chordoma of the proximal tibia with the help of brachyury, a molecule required for notochordal differentiation.

O'donnell P, Tirabosco R, Vujovic S, Bartlett W, Briggs TW, Henderson S, Boshoff C, Flanagan AM.

Skeletal Radiol. 2007 Jan;36(1):59-65. Epub 2006 Jun 30.

PMID:
16810540
16.

Skull base chordoma and chondrosarcoma: influence of clinical and demographic factors on prognosis: a SEER analysis.

Bohman LE, Koch M, Bailey RL, Alonso-Basanta M, Lee JY.

World Neurosurg. 2014 Nov;82(5):806-14. doi: 10.1016/j.wneu.2014.07.005. Epub 2014 Jul 5.

PMID:
25009165
17.

Temporal lobe (TL) damage following surgery and high-dose photon and proton irradiation in 96 patients affected by chordomas and chondrosarcomas of the base of the skull.

Santoni R, Liebsch N, Finkelstein DM, Hug E, Hanssens P, Goitein M, Smith AR, O'Farrell D, Efird JT, Fullerton B, Munzenrider JE.

Int J Radiat Oncol Biol Phys. 1998 Apr 1;41(1):59-68.

PMID:
9588918
18.

[Novel molecular aspects of chordomas].

Scheil-Bertram S.

Pathologe. 2014 Nov;35 Suppl 2:237-41. doi: 10.1007/s00292-014-1986-z. German.

PMID:
25394972
19.

Gain of chromosome 7 by chromogenic in situ hybridization (CISH) in chordomas is correlated to c-MET expression.

Walter BA, Begnami M, Valera VA, Santi M, Rushing EJ, Quezado M.

J Neurooncol. 2011 Jan;101(2):199-206. doi: 10.1007/s11060-010-0250-5. Epub 2010 Jul 10.

PMID:
20617367
20.

High-resolution whole-genome analysis of skull base chordomas implicates FHIT loss in chordoma pathogenesis.

Diaz RJ, Guduk M, Romagnuolo R, Smith CA, Northcott P, Shih D, Berisha F, Flanagan A, Munoz DG, Cusimano MD, Pamir MN, Rutka JT.

Neoplasia. 2012 Sep;14(9):788-98.

Supplemental Content

Support Center